In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group. Zusätzlich bieten wir Ihnen in diesem Bereich Bildmaterial und Informationen zu unseren Veranstaltungen. Als Überblick unserer Forschungstätigkeiten stehen zudem unsere Annual Scientific Reports hier für Sie zum Download bereit.
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer have been published in the Anticancer Drugs.
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment have been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.
We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.
A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.
A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.
Die erste Analyse der BMBC-Registerstudie zur Versorgung von Patientinnen mit Hirnmetastasen wurde im European Journal of Cancer veröffentlicht.
Priming the Immune System: Neoadjuvant Durvalumab Plus Chemotherapy May Be Beneficial in Triple-Negative Breast Cancer
A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.
Unser Review zur Endokrine Therapie in prämenopausale Patientinnen mit Hormone Rezeptor-positivem, HER2-negativem metastasiertem Brust Krebs wurde in The Oncologist publiziert.